tetano
Editor, Senior Moderator
Cardiovasc Endocrinol Metab
. 2020 Jun 11;9(3):110-120.
doi: 10.1097/XCE.0000000000000211. eCollection 2020 Sep.
Is it infection or rather vascular inflammation? Game-changer insights and recommendations from patterns of multi-organ involvement and affected subgroups in COVID-19
Antoine Fakhry AbdelMassih[SUP] 1 2 [/SUP], Aya Kamel[SUP] 3 [/SUP], Fady Mishriky[SUP] 3 [/SUP], Habiba-Allah Ismail[SUP] 3 [/SUP], Layla El Qadi[SUP] 3 [/SUP], Lauris Malak[SUP] 1 [/SUP], Miral El-Husseiny[SUP] 3 [/SUP], Mirette Ashraf[SUP] 3 [/SUP], Nada Hafez[SUP] 3 [/SUP], Nada AlShehry[SUP] 3 [/SUP], Nadine El-Husseiny[SUP] 4 5 [/SUP], Nora AbdelRaouf[SUP] 3 [/SUP], Noura Shebl[SUP] 3 [/SUP], Nouran Hafez[SUP] 3 [/SUP], Nourhan Youssef[SUP] 3 [/SUP], Peter Afdal[SUP] 3 [/SUP], Rafeef Hozaien[SUP] 3 [/SUP], Rahma Menshawey[SUP] 3 [/SUP], Rana Saeed[SUP] 3 [/SUP], Raghda Fouda[SUP] 6 7 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is a serious illness that has rapidly spread throughout the globe. The seriousness of complications puts significant pressures on hospital resources, especially the availability of ICU and ventilators. Current evidence suggests that COVID-19 pathogenesis majorly involves microvascular injury induced by hypercytokinemia, namely interleukin 6 (IL-6). We recount the suggested inflammatory pathway for COVID-19 and its effects on various organ systems, including respiratory, cardiac, hematologic, reproductive, and nervous organ systems, as well examine the role of hypercytokinemia in the at-risk geriatric and obesity subgroups with upregulated cytokines' profile. In view of these findings, we strongly encourage the conduction of prospective studies to determine the baseline levels of IL-6 in infected patients, which can predict a negative outcome in COVID-19 cases, with subsequent early administration of IL-6 inhibitors, to decrease the need for ICU admission and the pressure on healthcare systems. Video abstract: http://links.lww.com/CAEN/A24.
Keywords: coronavirus disease 2019; interleukin 6; microvascular inflammation; multi-system involvement; new management strategy; repurposed use of anti-interleukin.
. 2020 Jun 11;9(3):110-120.
doi: 10.1097/XCE.0000000000000211. eCollection 2020 Sep.
Is it infection or rather vascular inflammation? Game-changer insights and recommendations from patterns of multi-organ involvement and affected subgroups in COVID-19
Antoine Fakhry AbdelMassih[SUP] 1 2 [/SUP], Aya Kamel[SUP] 3 [/SUP], Fady Mishriky[SUP] 3 [/SUP], Habiba-Allah Ismail[SUP] 3 [/SUP], Layla El Qadi[SUP] 3 [/SUP], Lauris Malak[SUP] 1 [/SUP], Miral El-Husseiny[SUP] 3 [/SUP], Mirette Ashraf[SUP] 3 [/SUP], Nada Hafez[SUP] 3 [/SUP], Nada AlShehry[SUP] 3 [/SUP], Nadine El-Husseiny[SUP] 4 5 [/SUP], Nora AbdelRaouf[SUP] 3 [/SUP], Noura Shebl[SUP] 3 [/SUP], Nouran Hafez[SUP] 3 [/SUP], Nourhan Youssef[SUP] 3 [/SUP], Peter Afdal[SUP] 3 [/SUP], Rafeef Hozaien[SUP] 3 [/SUP], Rahma Menshawey[SUP] 3 [/SUP], Rana Saeed[SUP] 3 [/SUP], Raghda Fouda[SUP] 6 7 [/SUP]
Affiliations
- PMID: 32803145
- PMCID: PMC7410022
- DOI: 10.1097/XCE.0000000000000211
Abstract
Coronavirus disease 2019 (COVID-19) is a serious illness that has rapidly spread throughout the globe. The seriousness of complications puts significant pressures on hospital resources, especially the availability of ICU and ventilators. Current evidence suggests that COVID-19 pathogenesis majorly involves microvascular injury induced by hypercytokinemia, namely interleukin 6 (IL-6). We recount the suggested inflammatory pathway for COVID-19 and its effects on various organ systems, including respiratory, cardiac, hematologic, reproductive, and nervous organ systems, as well examine the role of hypercytokinemia in the at-risk geriatric and obesity subgroups with upregulated cytokines' profile. In view of these findings, we strongly encourage the conduction of prospective studies to determine the baseline levels of IL-6 in infected patients, which can predict a negative outcome in COVID-19 cases, with subsequent early administration of IL-6 inhibitors, to decrease the need for ICU admission and the pressure on healthcare systems. Video abstract: http://links.lww.com/CAEN/A24.
Keywords: coronavirus disease 2019; interleukin 6; microvascular inflammation; multi-system involvement; new management strategy; repurposed use of anti-interleukin.